WCG acquires CTMS internet platform for its growing network

By Maggie Lynch contact

- Last updated on GMT

(Image:Getty/Urupong)
(Image:Getty/Urupong)

Related tags: CTMS, Research, research network, WCG, Drug development, Transparency

WCG acquires Velos’ CTMS internet platform to provide drug development and research management to its large institutional research network.

WIRB-Copernicus Group (WCG) clinical service division’s acquisition of Velos eResearch will give WCG’s network access to clinical research simplification capabilities through clinical trial management software.

Velos eResearch manages institutional research by housing study status, patient enrollment, calendars, budgets, billing, and electronic data capture in one place. The company states the platform increases efficiency, transparency and accessibility of institutional research.

According to WCG, it partners with 93% of institutions and 90% of the academic medical centers that conduct research in the US. Donald Deieso, executive chairman and CEO of WCG, stated that the group serves more than 2,800 institutions.  

Through this partnership with the institutions, WCG states it facilitates drug development, providing solutions to increase efficiency and profitability of their research, as well as accelerating patient enrollment.

John McIlwain, co-founder and CEO of Velos, said that its clients are a “critical part of the clinical research ecosystem. It is our mission to break down the silos and administrative barriers slowing their progress and limiting their growth, to enable them to accelerate breakthroughs in clinical care.”

Velos will operate independently and retain its headquarters in Fremont, California. WCG will support Velos with access to capital, expertise and corporate operational support.

WCG has acquired and collaborated with multiple companies to expand its pharmacovigilance​, trial benchmarking​, and data monitoring​ services. 

Related news

Show more

Related products

show more

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars